Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen Pharmaceuticals Inc.

www.janssenpharmaceuticalsinc.com

Latest From Janssen Pharmaceuticals Inc.

Merck & Co. Will Manufacture J&J Vaccine, Other COVID-19 Medicines Under BARDA Deal

Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.

Coronavirus COVID-19 Manufacturing

Merck’s COVID Manufacturing Deal With US Government Goes Well Beyond J&J Vaccine

‘Wartime’ contract with BARDA will fund up to $268.8m in production site upgrades so Merck can also produce other COVID-19 vaccines and therapeutics as needed.

Coronavirus COVID-19 Manufacturing

Pfizer Embraces Biotech-Like Speed To Advance BCMA Bispecific

Chris Boshoff, Pfizer Oncology chief development officer, said lessons from the rapid pace of the company’s COVID-19 vaccine program are being applied to elranatamab and other cancer therapies.

Research and Development Strategies Business Strategies

Five New EU Filings Leave Starting Blocks at EMA

There is one orphan drug among the five new marketing authorization applications that the European Medicines Agency has under review. All five drugs will be reviewed under standard review timelines.

Europe Review Pathway
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register